Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDSET 1: KarXT + KarX-EC for cognitive impairment in mild to moderate Alzheimer's disease
2025-520746-30-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing KarXT + KarX-EC with Matching placebo (2 arms). Primary endpoints: Change from baseline in ADAS-Cog11 at Week 24 and CIBIC+ at Week 24. Planned start Nov 2025; status: authorised.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-520746-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520746-30-00.